VANCOUVER, British Columbia & FOUNTAIN VALLEY, Calif.--(BUSINESS WIRE)--Contextual Genomics, a leading cancer genomics company, and Lab Genomics, a personalized medicine company providing state of the art molecular genetic testing in Southern California, announced that they have signed an agreement enabling Lab Genomics to offer Contextual Genomics’ quality assured Next Generation Sequencing (NGS) based ctDNA cancer genomic testing to patients in Southern California and other parts of the United States.
Under the terms of their agreement, Lab Genomics will offer the FOLLOW IT® panel, a test detecting cell-free circulating tumour DNA in plasma to patients diagnosed with cancer. The FOLLOW IT panel is a multiplex, NGS genomic assay designed for rapid deployment into labs around the world. The FOLLOW IT assay evaluates the mutation status of cell-free circulating tumour, identifying the somatic mutations that have the greatest potential to impact treatment decisions.
Michael Ball, Contextual Genomics’ Chief Executive Officer, said “We are pleased to announce this important relationship with Lab Genomics. The availability of quality-assured cost-effective rapid turnaround time ctDNA testing as a result of this partnership will be of tremendous benefit to many patients suffering from solid tumour cancers, avoiding the need for more invasive tissue biopsies. We look forward to working with Lab Genomics to bring this more precise personalized care to cancer patients within their territory.”
“At Lab Genomics, our mission is to deliver a suite of unmatched molecular diagnostic services to our customers, to provide preventive, predictive, personalized services,” said Leena Dalal, Founder of Lab Genomics. “This partnership with Contextual Genomics, adding FOLLOW IT liquid biopsy cancer testing for our customers, provides a critical less invasive alternative testing option for cancer patients where tissue biopsy is difficult or not available. We look forward to continuing to support the best quality of life possible for all patients and FOLLOW IT will be an important part of our oncology offering.”
About Contextual Genomics (www.contextualgenomics.com):
Contextual Genomics develops cost-effective and clinically actionable molecular tests that guide diagnosis and treatment of cancer. These customized tests are offered by our partner laboratories around the world with Contextual Genomics conducting cloud-based bioinformatics services via a SaaS model. The collection of data via this robust network of partners and the use of machine-learning tools allows Contextual Genomics to improve patient care through improved clinical trial enrollment and new treatment algorithms. Contextual Genomics is founded and managed by global leaders in cancer medicine and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.
About Contextual Genomics’ Products:
Contextual Genomics has developed the FIND IT® and FOLLOW IT® cancer panels. Both panels are multiplex, next-generation sequencing genomic assays designed for rapid deployment into labs around the world. Both FIND IT and FOLLOW IT evaluate the mutation status of tumour DNA (FIND IT for solid tumours; FOLLOW IT for cell-free circulating tumour DNA in plasma) at 146 well-characterized positions, identifying the somatic mutations that have the greatest potential to impact treatment decisions. QUALITY NEXUS® is a quality control system embedded into all FIND IT and FOLLOW IT assays and into Contextual Genomics’ cloud-based analysis engine. FIND IT and FOLLOW IT physician reports provide clear information on test interpretation and linkages to current therapeutic options.
About Lab Genomics (www.labgenomic.com):
Lab Genomics, LLC was cultivated with the ideal in mind of providing state of the art molecular genetic testing with the end goal of the best quality of life possible for the patient. Lab Genomics is focused on delivering individualized medical care through its robust molecular and genetics diagnostics. The Lab Genomics team are highly qualified experts in the medical and genetics fields.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.